Radioiodine: The Classic Theranostic Agent

Silberstein, Edward B.

doi:10.1053/j.semnuclmed.2011.12.002

Cited by 83 publications

(41 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…325,326 Major strides have been made in understanding the underlying biology of cancer and improving methods for designing and synthesising targeted theranostic drugs. For example, metaiodobenzylguanidine has been used for many years for diagnostic imaging and treatment of neuroblastoma, paraganglioma, and phaeochromocytoma.…”

Section: Nuclear Medicine and Imagingmentioning

confidence: 99%

Future cancer research priorities in the USA: a Lancet Oncology Commission

Jaffee

Dang

Agus

et al. 2017

The Lancet Oncology

176

123

View full text Add to dashboard Cite

We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.

show abstract

Section: Nuclear Medicine and Imagingmentioning

confidence: 99%

Future cancer research priorities in the USA: a Lancet Oncology Commission

Jaffee

Dang

Agus

et al. 2017

The Lancet Oncology

176

123

View full text Add to dashboard Cite

show abstract

“…For example, the use of intravenous contrast in CT scans contains a large iodine load which may interfere with RAI scanning and therapy for several months. While several iodine isotopes exist, the most effective form used in adjuvant treatment for papillary thyroid cancer is I-131 [11]. The efficacy of I-131 also depends on the amount of thyroid tissue left behind at surgery.…”

Section: Mechanism Of Radioiodinementioning

confidence: 99%

To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients

Carballo

Quiros

2012

Journal of Oncology

View full text Add to dashboard Cite

Radioactive iodine (RAI) is used in treatment of patients with differentiated papillary and follicular thyroid cancer. It is typically used after thyroidectomy, both as a means of imaging to detect residual thyroid tissue or metastatic disease, as well as a means of treatment by ablation if such tissue is found. In this paper, we discuss the indications for and the mechanisms of RAI in the treatment of patients with thyroid cancer. We discuss the attendant risks and benefits that come with its use, as well as techniques used to optimize its effectiveness as an imaging tool and a therapeutic modality.

show abstract

“…Examples include radio-pharmaceuticals that pair diagnostic 111 In/ 68 Ga with therapeutic 90 Y/ 177 Lu or incorporate different isotopes of iodine, with diagnostic 123 I/ 124 I and therapeutic 131 I. 2,3 However, these approaches suffer from limitations due to the potential for differences in diagnostic/therapeutic agent biodistribution resulting from the use of different radiolabel elements or, in the case of the 124 I/ 131 I pair, problems with deiodination and subsequent thyroid localization and damage following therapeutic dose administration.…”

Section: Introductionmentioning

confidence: 99%

High Yield Production and Radiochemical Isolation of Isotopically Pure Arsenic-72 and Novel Radioarsenic Labeling Strategies for the Development of Theranostic Radiopharmaceuticals

Ellison¹,

Barnhart²,

Chen³

et al. 2015

Bioconjugate Chem.

View full text Add to dashboard Cite

Radioisotopes of arsenic are of considerable interest to the field of nuclear medicine with unique nuclear and chemical properties making them well-suited for use in novel theranostic radiopharmaceuticals. However, progress must still be made in the production of isotopically pure radioarsenic and in its stable conjugation to biological targeting vectors. This work presents the production and irradiation of isotopically enriched 72Ge(m) discs in an irrigation-cooled target system allowing for the production of isotopically pure 72As with capability on the order of 10 GBq. A radiochemical separation procedure isolated the reactive trivalent radioarsenic in a small volume buffered aqueous solution, while reclaiming 72Ge target material. The direct thiol-labeling of a monoclonal antibody resulted in a conjugate exhibiting exceptionally poor in vivo stability in a mouse model. This prompted further investigations to alternative radioarsenic labeling strategies, including the labeling of the dithiol-containing chelator dihydrolipoic acid, and thiol-modified mesoporous silica nanoparticles (MSN-SH). Radioarsenic-labeled MSN-SH showed exceptional in vivo stability toward dearsenylation.

show abstract

Radioiodine: The Classic Theranostic Agent

Cited by 83 publications

References 40 publications

Future cancer research priorities in the USA: a Lancet Oncology Commission

Future cancer research priorities in the USA: a Lancet Oncology Commission

To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients

High Yield Production and Radiochemical Isolation of Isotopically Pure Arsenic-72 and Novel Radioarsenic Labeling Strategies for the Development of Theranostic Radiopharmaceuticals

Contact Info

Product

Resources

About